Healthcare / Drug Manufacturers - Specialty & GenericTaipei Exchange
$62.80
-0.30 (-0.47%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $137.7M · quality 82.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
45/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.2B
P/E
9.9x
↓EV/EBITDA
5.4x
↓ROE
27.4%
↑Gross Margin
43.4%
↓Debt/Equity
0.20
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+4.9%
FCF CAGR
+5.2%
FCF margin
19.7%
FCF / Net income
1.17x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $700.1M · net income $117.3M · FCF $137.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $700.1M | $700.1M | $695.1M | $709.1M | $606.5M |
| Net Income | $117.3M | $117.3M | $131.6M | $158.8M | $111.3M |
| EBITDA | $174.1M | $174.1M | $195.0M | $228.3M | $178.8M |
| EPS | — | — | 7.12 | 8.58 | 6.01 |
| Gross Margin | 43.4% | 43.4% | 45.4% | 49.0% | 43.6% |
| Operating Margin | 20.3% | 20.3% | 22.9% | 27.7% | 22.2% |
| Net Margin | 16.8% | 16.8% | 18.9% | 22.4% | 18.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.20 | 0.20 | 0.23 | 0.25 | 0.26 |
| Current Ratio | 1.99 | 1.99 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $137.7M | $137.7M | $128.8M | $195.4M | $118.3M |
| Returns | |||||
| ROE | 27.4% | 27.4% | 29.9% | 37.1% | 30.8% |
| Valuation | |||||
| P/E | 9.86 | 9.86 | 12.64 | 12.00 | 10.05 |
| EV/EBITDA | 5.42 | 5.42 | 7.53 | 7.50 | 5.64 |
| P/B | 2.71 | 2.71 | 3.79 | 4.45 | 3.09 |
| Growth & Yield | |||||
| Revenue Growth | 0.7% | 0.7% | -2.0% | 16.9% | — |
| EPS Growth | — | — | -17.0% | 42.8% | — |
| Dividend Yield | 7.9% | 7.9% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-31.2%
Start / end P/E
n/dx → n/dx
EPS bridge
7.12 → n/d
Residual
-39.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.